TORONTO, March 24, 2014 /CNW/ - Concordia Healthcare Corp. ("Concordia") (TSX: CXR) (OTCQX: CHEHF) today announced it will release its 2013 year-end financial results on Monday, March 31, 2014, before market open. The Company will subsequently hold a conference call on Monday, March 31, 2014, at 8:30 a.m. ET hosted by Mr. Mark Thompson, President and Chief Executive Officer, and Mr. Leith Tessy, Chief Financial Officer. A question-and-answer session will follow the corporate update.
|CONFERENCE CALL DETAILS|
|DATE:||Monday, March 31, 2014|
|TIME:||8:30 a.m. ET|
|DIAL-IN NUMBER:||(647) 427-7450 or (888) 231-8191|
|TAPED REPLAY:||(416) 849-0833 or (855) 859-2056|
This call is being webcast and can be accessed from the Concordia website at www.concordiarx.com. An archived replay of the webcast will be available for one year.
Concordia is a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs and medical devices for the diabetic population. The company's legacy pharmaceutical business consists of an ADHD-treatment drug, Kapvay® (clonidine extended release tablets), Ulesfia® (benzyl alcohol) Lotion a Head Lice Treatment, and an Asthma-related medication, Orapred ODT® (prednisolone sodium phosphate orally disintegrating tablets). Concordia's Specialty Healthcare Distribution (SHD) division (Complete Medical Homecare) distributes medical supplies targeting diabetes and related conditions. Concordia's orphan division, Pinnacle, markets Photofrin® in the United States.
Concordia operates out of facilities in Oakville, Ontario, Lenexa, Kansas (near Kansas City, Missouri), Bannockburn, (near Chicago), Illinois and Bridgetown, Barbados.
SOURCE: Concordia Healthcare Corp.
For further information:
For more information, please visit www.concordiarx.com or contact:
Kristen Van Vogt
416-815-0700 x 244
416-815-0700 x 225